Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No

Executive Summary

The oncology player missed out on the first round of immune checkpoint inhibition and now some investors are wondering if the pharma needs to buy a rival to catch up. During the company’s second quarter sales call CEO Jimenez insisted Novartis has the internal expertise to execute.

Advertisement

Related Content

Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Juno ROCKETs On Fast Clinical Hold Resolution
Aetna: Entresto’s Label Enabled Outcome-Based Risk Share
Novartis Oncology Strategy: Focus On The Microenvironment
Novartis Oncology Strategy: Focus On The Microenvironment
Entresto US Sales Barriers Set To Be Removed By Strong Guidance
Novartis Rejiggers Pharma To Favor Oncology
'This Isn't The Past Novartis,' Jimenez Tells JPM Conference

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096932

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel